

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: February 28, 2008    Signature: Jeanne M. Brashear/56.301  
(Jeanne M. Brashear)

**REPLY UNDER 37 C.F.R § 1.116  
EXPEDITED PROCEDURE  
TECHNOLOGY CENTER 1644**

Docket No.: 28967/5680D  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Marc G. Achen et al.

Application No.: 10/627,631

Confirmation No.: 3314

Filed: July 28, 2003

Art Unit: 1644

For: Methods For Treating Neoplastic Disease  
Characterized By Vascular Endothelial Growth  
Factor D Expression, For Screening For  
Neoplastic Disease or Metastatic Risk and For  
Maintaining Vascularization of Tissue

---

Examiner: P. N. Huynh

**AMENDMENT AFTER FINAL OFFICE ACTION UNDER 37 C.F.R. § 1.116**

MS AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INTRODUCTORY COMMENTS**

This paper is being filed in response to the Final Office Action mailed October 31, 2007, finally rejecting claims 9-13, 41 and 45-47. This response is timely filed in view of the petition for a one-month extension of time and the appropriate fee submitted herewith.

The present amendment complies with 37 C.F.R. § 1.116(b)(1) and (2) in either eliminating issues for appeal or in placing issues in better form for appeal. Accordingly, the Applicants request that the Examiner exercise discretion in favor of entering the present amendment.

**The current listing of claims** begins on page 2 of this paper.

**Remarks/Arguments** begin on page 4 of this paper.